SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending amid community discussions about deep-sea mining and speculation around potential government support and regulatory approvals. Investors are closely watching for news and catalysts that could impact the company's future, while also debating the merits and risks of shorting the stock. Some are also pointing to potential positive impacts with a new US department of critical minerals.

About Mistery On Cro $MERY was born with the idea of being a meme coin on Cronos chain during the exploding 2024 meme coin season. The founder is David Bui, a well-known and seasoned #crofam $CRO investor on Cryptocom products and a big -well respected- personality on X. David minted “Mistery On CRO” on Cronos blockchain with the purpose of making this chain much better, more popular and specially more fun, but aside from serving as a mere “meme”, $MERY has the ultimate goal of also being a utility token that the founder and the team behind will push to bring many benefits to loyal hodlers. Launched in 27/3/2024 at Sydney, Australia, local time 21h00, the 690,000 $CRO presale sold out within 2 hours. The founder burned the LP to a dead wallet and the contract ownership was renounced. $MERY during its first week of launch got instant traction from the OG #crofam community who jumped in and secured bags. We are now a thriving community that will help nurturing and growing the project by sharing with more and more Web3 users.

Mistery

$MERY is trending as a 'native community meme' coin on crypto.com/us, fueled by discussions around the exchange's significant coin ownership and locked developer coins, which are seen as 'rug-proof' factors. Community members are also discussing its close ties with $CRO and its potential for upward movement.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy ($SWEAT) is trending as the community discusses its potential and utility related to earning crypto through physical activity. Many believe it is currently undervalued and are waiting patiently for it to gain traction. Discussions also revolve around its potential as a "universal gas token" across multiple blockchains.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) Public Ltd Co - Ordinary Shares - Class A

SMX is trending due to a recent surge in price and volume, sparking discussions about a potential short squeeze and its future prospects. Community members are debating the stock's fundamentals, dilution history, and potential for further gains, while some highlight recent news and partnerships as catalysts for the movement. The stock's volatile history and high short interest are also fueling speculation and trading activity.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

LABU is trending due to renewed bullish sentiment and concentrated purchasing power within the biotech sector, driving prices upward. The community is actively discussing the potential for AI and pharmaceutical advancements to fuel further rallies. However, some caution that a pullback is coming.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin ($CRO) is trending as traders discuss its potential, with some focusing on its association with meme coin $MERY and others expressing frustration over its price action relative to Bitcoin's movements.  Broader discussions involve speculation around a potential CRO ETF and the impact of Trump Media's reported $CRO holdings.  Community members are weighing the potential for future growth against concerns about past performance.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending as community members highlight its strong community and meme-focused culture within the $PUMP ecosystem on the Solana blockchain. Discussions revolve around the concept of being 'infected' with the PumpMindVirus, a fun and relatable narrative. The community is actively creating memes and expressing bullish sentiment, anticipating future growth and broader recognition.

Surgery Partners, Inc. is healthcare services holding company, which engages in the provision of solutions for surgical and related ancillary care in support of its patients and physicians. It operates through the following business segments: Surgical Facility Services, Ancillary Services, and Optical Services. The Surgical Facility Services segment consists of the operation of ambulatory surgery centers and surgical hospitals, including anesthesia services of the company. The Ancillary Services segment operates a diagnostic laboratory and multi-specialty physician practices. The Optical Services segment involves an optical laboratory and an optical products group purchasing organization. The company was founded in 2004 and is headquartered in Brentwood, TN.

Surgery Partners Inc

Surgery Partners is trending due to a mix of factors, including potential M&A activity and recent ratings updates from analysts. Community members are actively discussing options activity and potential buyout scenarios, especially following a rejected offer earlier this year. Some are also pointing to a new COO and valuation metrics as potential catalysts.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is trending despite a post-earnings plunge, with analysts predicting a potential upside. Community members are actively discussing whether this presents a buying opportunity or if broader market factors and valuation concerns will continue to weigh on the stock. The cybersecurity sector's performance and Zscaler's position within it are also key talking points.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy ($FLNC) is trending amid analyst upgrades and discussions around BlackRock's potential acquisition of AES, a major shareholder. Community members are highlighting the company's strong positioning in the energy storage sector, particularly related to AI-driven data center power needs and domestic content advantages. Despite some mixed sentiment around earnings, the focus remains on future growth and the potential for a short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ascendiant Capital Markets Cuts Plus Therapeutics (NASDAQ:PSTV) Price Target to $19.00

Ascendiant Capital Markets decreased their price target on shares of Plus Therapeutics from $21.00 to $19.00 and set a "buy" rating on the stock in a research note on Friday...

&nbsp;November 20, 2025<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.plustherapeutics.com/node/17491/pdf">PDF Version</a>HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=-LjgaMRZ499BxpnVFdK1_OIruUYH174LnCXs-fy9J1I_eFQqC3JpTBwOvH766dIT1nH5xLfntIINbP5tEdkB0SDLQG78HFGAOU5BkEJHktWlDyLHpCuy4sMdy9V6Ic4WNMutQlg4-mtVdYtWYaiL2IGkfMeZRCJwGfExniMB_2c8rF2BDTDExok63zegxo0Zzz8pCRIM_zGVoZ1pjMraVCsb47ACHDjHfm535tp8HDAGNMMlGzQxU4v50bSczESWKo6x314ti5HzsTYfN5TjFKj_R0Svs0TsL0Fpuw4o_V2QfDL515ej-QxrOcQDGzj83Xv55B3FzhnQtPM8CwzhHpEEtGvzFWKaNufvlmTXXGcjoyYpySS0ASePbFZjDn0SFCVDnbn2ujI2mvrDFn_YPj4uRtUZKd_u84vRPxhML9hM-8bd2N6am39WyHccsrghDSIS-9PtjI-w5QT1fbwrMTOplD0Zgp5-7lDPMm_u6rKd-HDKnSTsf1VW9kP-ssxp">Plus Therapeutics, Inc.</a>&nbsp;(Nasdaq:&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=Qc6X8S3RzScKVxvNu5_ceEM5GEv1Pptj0kvVK2trVYTrKl52rKHptUJcMeFv_r8m6XJ1xYecZnTL9qsMJK-c4D7wONMnr4cOMHuhbyC-B_5ohVVGYSzEJF3Bkl7p1l7wVA64zTIak8hwab7N7Mq556tOQzJlP6kOnE85RNx-iO3w5Wba49-0HAevN_Q0AzurlwzNjWv5cenpZgxc6bFvdrGmTjJRaW_JSEuTLAnXmNlti0LfISAeX284Eg18Lpu6kaosboSHHlT-jVrzzC9bF_XHIR2lKjlwRHyA34hiRVgqvNNrk9BKENa4lSbOz0hxdMgude4ZKO_7LMkYeJ78D5qOqeh8jDUAgckGvzK6XSj4sPM3rAs4MMrV6u79J2HmkaRunbqmC4i9TaFzG2JElk80i-xPqB7Ud8a_0MZs9BXT5C7FRTNYAtbyUh38Wl1-">PSTV</a>) (“Plus” or the “Company”), announced today that it has signed a national agreement with Humana, Inc. (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=Ckx5KRl7GkjOTsknevCsv0V8yLayXt9wPOfKjhKbZbbUPUtJYQQ1s_3WMPrcWwJKkvtnm3wVcl2NqQk3TgY1p2feIGsp1Q-lDBhIyjds9Qo=">HUM</a>), effective&nbsp;October 29, 2025, covering approximately 16 million people throughout&nbsp;the United States, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) laboratory developed test (LDT). This brings CNSide CSF TCE LDT total policy coverage to 67 million people.The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide® over standard of care has been shown in 9 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use.More than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (92%) and specificity (95%), while influencing treatment decisions in 90% of cases.This test is available exclusively through CNSide Diagnostics, LLC. as a testing service provided to health care professionals in the U.S.About CNSide Diagnostics, LLC&nbsp; CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases. For more information, visit&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=_L7AJZWxKXphoarOFZy8Z85jinISrbvcaCeYclceVpAt9mO3Wi78ljN4HTR9BVI1smJG5x77F_beqPHrp5vSTUx_fkwpPQaECwHXeOdYGN4=">https://www.cnside-dx.com/</a>.About Plus Therapeutics Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=_L7AJZWxKXphoarOFZy8Z35nW-kNODbXQZtlDECdtGDGWCcawXezTzcic5Wa0-GT7YTxFESUvgVo1SXipvsyvJqzICHTRIfUoONu9xOH9uwwt2yHEFxsHOOelgYY9iSs">https://www.plustherapeutics.com</a>.About HumanaHumana Inc. (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=sVqa190sv-OGip6yFjYGO0t_cm6VKwY3aysRDxYxSjt0DTCbL2OqMK2Oz0V0BVN0kxVxe1yu5iCIPHAl4xJijJT_ANoSx8Di9opJClAXJ3U=">HUM</a>) is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.Forward-Looking Statements This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.Investor Contact CORE IR <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:investor@plustherapeutics.com">investor@plustherapeutics.com</a>Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

CNSide Diagnostics, a Plus Therapeutics subsidiary, secured a national agreement with Humana to provide its CNSide CSF Tumor Cell Enumeration test, expanding coverage to 67 million people.

Others

Plus Therapeutics (NASDAQ:PSTV) Receives "Buy" Rating from D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and set a $5.00 target price on shares of Plus Therapeutics in a research note on Thursday...

Plus Therapeutics (NASDAQ:PSTV) Downgraded to "Hold" Rating by Zacks Research

Zacks Research lowered shares of Plus Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday...

Plus Therapeutics (NASDAQ:PSTV) CFO Andrew John Hugh Macintyr Sims Buys 20,000 Shares

Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) CFO Andrew John Hugh Macintyr Sims acquired 20,000 shares of the firm's stock in a transaction on Tuesday, November 4th. The shares were bought...

Plus Therapeutics (NASDAQ:PSTV) CFO Buys $10,200.00 in Stock

Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) CFO Andrew John Hugh Macintyr Sims purchased 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, November 4th. The...

Plus Therapeutics (PSTV) Reports Q3 Loss, Lags Revenue Estimates

Plus (PSTV) delivered earnings and revenue surprises of -100.00% and -36.79%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Beats Q3 Earnings Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of +3.92% and -2.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge PR Newswire VANCOUVER, BC, Oct. 15, 2025 Equity Insider News...

Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics

Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

PSTV
Plus Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PSTV News

PSTVPlus Therapeutics Inc